ES2274712B1 - Nuevos derivados imidazopiridina. - Google Patents
Nuevos derivados imidazopiridina. Download PDFInfo
- Publication number
- ES2274712B1 ES2274712B1 ES200502433A ES200502433A ES2274712B1 ES 2274712 B1 ES2274712 B1 ES 2274712B1 ES 200502433 A ES200502433 A ES 200502433A ES 200502433 A ES200502433 A ES 200502433A ES 2274712 B1 ES2274712 B1 ES 2274712B1
- Authority
- ES
- Spain
- Prior art keywords
- pyridin
- imidazo
- fluoropyridin
- pyridine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 110
- 238000011282 treatment Methods 0.000 claims abstract description 22
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 6
- 229960005305 adenosine Drugs 0.000 claims abstract description 6
- 208000006673 asthma Diseases 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 230000006872 improvement Effects 0.000 claims abstract description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 5
- 206010038923 Retinopathy Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 208000026935 allergic disease Diseases 0.000 claims abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 4
- 229940044551 receptor antagonist Drugs 0.000 claims abstract description 4
- 239000002464 receptor antagonist Substances 0.000 claims abstract description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 3
- -1 piperidinylmethyl Chemical group 0.000 claims description 54
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229940043355 kinase inhibitor Drugs 0.000 claims description 8
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 230000001575 pathological effect Effects 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- NEKLJQZEHUUVND-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1CC1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 NEKLJQZEHUUVND-UHFFFAOYSA-N 0.000 claims description 4
- LGHGHJRAFKVZEZ-UHFFFAOYSA-N 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-yl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 LGHGHJRAFKVZEZ-UHFFFAOYSA-N 0.000 claims description 4
- MMAZBBTVGGVGIM-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-(4-methoxyphenyl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 MMAZBBTVGGVGIM-UHFFFAOYSA-N 0.000 claims description 4
- QCAGPDXBMNNMBH-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyridin-4-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C=1C=CN=CC=1)=N2 QCAGPDXBMNNMBH-UHFFFAOYSA-N 0.000 claims description 4
- 229940123053 Adenosine A2b receptor antagonist Drugs 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- CMGXDPCRFRFEQJ-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C=1C=C3OCCOC3=CC=1)=N2 CMGXDPCRFRFEQJ-UHFFFAOYSA-N 0.000 claims description 3
- LOUMZSUMBGYUSB-UHFFFAOYSA-N 2-(2,4-dichloro-5-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=C(Cl)C(F)=CC(C=2NC3=NC(=C(C=4C(=CN=CC=4)F)C=C3N=2)C=2C=NC=CC=2)=C1Cl LOUMZSUMBGYUSB-UHFFFAOYSA-N 0.000 claims description 3
- KAZUSWOHYPVEKM-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 KAZUSWOHYPVEKM-UHFFFAOYSA-N 0.000 claims description 3
- WELTYXZXXJRVNV-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 WELTYXZXXJRVNV-UHFFFAOYSA-N 0.000 claims description 3
- JMNOPWJKGOGKSU-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)propan-2-yl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C=1C=C(Cl)C=CC=1C(C)(C)C(NC1=NC=2C=3C=NC=CC=3)=NC1=CC=2C1=CC=NC=C1F JMNOPWJKGOGKSU-UHFFFAOYSA-N 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- CUEWSJXBADPEGT-UHFFFAOYSA-N 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 CUEWSJXBADPEGT-UHFFFAOYSA-N 0.000 claims description 3
- MUUGCFKLOVKSDN-UHFFFAOYSA-N 5-(3-chloropyridin-4-yl)-2-(4-fluorophenyl)-6-(3-fluoropyridin-4-yl)-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C(=CN=CC=3)Cl)N=C2N1 MUUGCFKLOVKSDN-UHFFFAOYSA-N 0.000 claims description 3
- SLTIUZBNBDSTRB-UHFFFAOYSA-N 5-(3-chloropyridin-4-yl)-2-(4-fluorophenyl)-6-pyridin-4-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC2=CC(C=3C=CN=CC=3)=C(C=3C(=CN=CC=3)Cl)N=C2N1 SLTIUZBNBDSTRB-UHFFFAOYSA-N 0.000 claims description 3
- NVIMJSZNQGYNMM-UHFFFAOYSA-N 5-(3-chloropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound ClC1=CN=CC=C1C(C(=C1)C=2C=CN=CC=2)=NC2=C1NC(=O)N2 NVIMJSZNQGYNMM-UHFFFAOYSA-N 0.000 claims description 3
- AUHKQACTCSTFNA-UHFFFAOYSA-N 6-(3-chloropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)Cl)=C(C=3C=CN=CC=3)N=C2N1 AUHKQACTCSTFNA-UHFFFAOYSA-N 0.000 claims description 3
- HEQZBTGQAYDCKB-UHFFFAOYSA-N 6-(3-chloropyridin-4-yl)-5-pyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound ClC1=CN=CC=C1C(C(=N1)C=2C=CN=CC=2)=CC2=C1NC(=O)N2 HEQZBTGQAYDCKB-UHFFFAOYSA-N 0.000 claims description 3
- CSPSBRHWRRLXMI-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-2-[4-(trifluoromethyl)phenyl]-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C=1C=CC(=CC=1)C(F)(F)F)=N2 CSPSBRHWRRLXMI-UHFFFAOYSA-N 0.000 claims description 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 3
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims description 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 3
- 102100037346 Substance-P receptor Human genes 0.000 claims description 3
- 102000000551 Syk Kinase Human genes 0.000 claims description 3
- 108010016672 Syk Kinase Proteins 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- ZQYYXKXTXVOABI-UHFFFAOYSA-N methyl 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 ZQYYXKXTXVOABI-UHFFFAOYSA-N 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- LQIUQSPMXZDVKL-UHFFFAOYSA-N 2-(3-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CC=CC(C=2NC3=NC(=C(C=4C(=CN=CC=4)F)C=C3N=2)C=2C=NC=CC=2)=C1 LQIUQSPMXZDVKL-UHFFFAOYSA-N 0.000 claims description 2
- IRSOCOIGTZSSKE-UHFFFAOYSA-N 2-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)C1=C(C(=O)O)C=CC=C1 IRSOCOIGTZSSKE-UHFFFAOYSA-N 0.000 claims description 2
- SIBXJJSFYUSKKF-UHFFFAOYSA-N 3-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2NC3=NC(=C(C=4C(=CN=CC=4)F)C=C3N=2)C=2C=NC=CC=2)=C1 SIBXJJSFYUSKKF-UHFFFAOYSA-N 0.000 claims description 2
- NDWAVYFGVKBSTQ-UHFFFAOYSA-N 3-[[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridin-2-yl]amino]benzoic acid Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)NC=1C=C(C(=O)O)C=CC=1 NDWAVYFGVKBSTQ-UHFFFAOYSA-N 0.000 claims description 2
- FFLNKDCZUXSYGW-UHFFFAOYSA-N 3-[[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridin-2-yl]methyl]benzoic acid Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)CC=1C=C(C(=O)O)C=CC=1 FFLNKDCZUXSYGW-UHFFFAOYSA-N 0.000 claims description 2
- IBSMTARMKOSAMM-UHFFFAOYSA-N 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-yl]morpholine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(N1CCOCC1)=N2 IBSMTARMKOSAMM-UHFFFAOYSA-N 0.000 claims description 2
- ITIYCIWYRCMLIT-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2,5-dipyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C=1C=NC=CC=1)=N2 ITIYCIWYRCMLIT-UHFFFAOYSA-N 0.000 claims description 2
- NUVBINOYONMEQH-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-(1-methylpiperidin-4-yl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridine Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)C1CCN(CC1)C NUVBINOYONMEQH-UHFFFAOYSA-N 0.000 claims description 2
- GKZOHQSYAVKZSE-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-(3-methylphenyl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridine Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)C1=CC(=CC=C1)C GKZOHQSYAVKZSE-UHFFFAOYSA-N 0.000 claims description 2
- IRXYSYPIUJXRSJ-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-(4-methylpiperazin-1-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1CN(C)CCN1C1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 IRXYSYPIUJXRSJ-UHFFFAOYSA-N 0.000 claims description 2
- BUFGKIPVEPORBM-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-[(1-methylpiperidin-4-yl)methyl]-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridine Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)CC1CCN(CC1)C BUFGKIPVEPORBM-UHFFFAOYSA-N 0.000 claims description 2
- DGLDYJZHEFNOMS-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-[(3-methylphenyl)methyl]-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridine Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)CC1=CC(=CC=C1)C DGLDYJZHEFNOMS-UHFFFAOYSA-N 0.000 claims description 2
- JVJZXCPOFNLDOW-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C=1C=C(F)C(=CC=1)C(F)(F)F)=N2 JVJZXCPOFNLDOW-UHFFFAOYSA-N 0.000 claims description 2
- BZCXEJVUFFLKFL-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-N-(1-methylpiperidin-4-yl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridin-2-amine Chemical compound FC=1C=NC=CC=1C=1C=C2C(=NC=1C=1C=NC=CC=1)NC(=N2)NC1CCN(CC1)C BZCXEJVUFFLKFL-UHFFFAOYSA-N 0.000 claims description 2
- JNJZPKODYHXOKE-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-n,5-dipyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-amine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(NC=1C=NC=CC=1)=N2 JNJZPKODYHXOKE-UHFFFAOYSA-N 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000007885 bronchoconstriction Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- IBLFTIBUHMOLGB-UHFFFAOYSA-N n-(4-chlorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-amine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(NC=1C=CC(Cl)=CC=1)=N2 IBLFTIBUHMOLGB-UHFFFAOYSA-N 0.000 claims description 2
- CVKYNSKSNYSKPL-UHFFFAOYSA-N n-(4-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC2=CC(C=3C(=CN=CC=3)F)=C(C=3C=NC=CC=3)N=C2N1 CVKYNSKSNYSKPL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 2
- UIIMBCQUZAGZOW-UHFFFAOYSA-N 2-cyclohexyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridine 6-(3-fluoropyridin-4-yl)-2-methyl-5-pyridin-3-yl-1H-imidazo[4,5-b]pyridine Chemical compound FC=1C=NC=CC1C=1C=C2C(=NC1C=1C=NC=CC1)NC(=N2)C.C2(CCCCC2)C2=NC=1C(=NC(=C(C1)C1=C(C=NC=C1)F)C=1C=NC=CC1)N2 UIIMBCQUZAGZOW-UHFFFAOYSA-N 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- STRHNGYZIUTJMX-UHFFFAOYSA-N C1(CC1)C1=NC=2C(=NC(=C(C2)C2=C(C=NC=C2)F)C=2C=NC=CC2)N1.FC=1C=NC=CC1C=1C=C2C(=NC1C=1C=NC=CC1)NC(N2)=O Chemical compound C1(CC1)C1=NC=2C(=NC(=C(C2)C2=C(C=NC=C2)F)C=2C=NC=CC2)N1.FC=1C=NC=CC1C=1C=C2C(=NC1C=1C=NC=CC1)NC(N2)=O STRHNGYZIUTJMX-UHFFFAOYSA-N 0.000 claims 1
- RUALRBPLXGRFCY-UHFFFAOYSA-N ClC=1C=NC=CC1C=1C=C2C(=NC1C=1C=NC=CC1)NC(N2)=O.FC2=CC=C(C=C2)C2=NC=1C(=NC(=C(C1)C1=CC=NC=C1)C=1C=NC=CC1)N2 Chemical compound ClC=1C=NC=CC1C=1C=C2C(=NC1C=1C=NC=CC1)NC(N2)=O.FC2=CC=C(C=C2)C2=NC=1C(=NC(=C(C1)C1=CC=NC=C1)C=1C=NC=CC1)N2 RUALRBPLXGRFCY-UHFFFAOYSA-N 0.000 claims 1
- HJFBXUPSDXRIHW-UHFFFAOYSA-N FC=1C=NC=CC1C1=C(C=C2C(=N1)NC(N2)=O)C2=CC=NC=C2.N2=CC=C(C=C2)C2=C(C=C1C(=N2)NC(N1)=O)C1=CC=NC=C1 Chemical compound FC=1C=NC=CC1C1=C(C=C2C(=N1)NC(N2)=O)C2=CC=NC=C2.N2=CC=C(C=C2)C2=C(C=C1C(=N2)NC(N1)=O)C1=CC=NC=C1 HJFBXUPSDXRIHW-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 5
- 206010014561 Emphysema Diseases 0.000 abstract description 4
- 230000003042 antagnostic effect Effects 0.000 abstract description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 3
- 206010063837 Reperfusion injury Diseases 0.000 abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 80
- 239000000543 intermediate Substances 0.000 description 79
- 239000000203 mixture Substances 0.000 description 69
- 238000000034 method Methods 0.000 description 64
- 238000005481 NMR spectroscopy Methods 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 55
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 239000007787 solid Substances 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 34
- 239000002904 solvent Substances 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000005232 imidazopyridines Chemical class 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- NLTIETZTDSJANS-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC=C1 NLTIETZTDSJANS-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 6
- OGFQRMVUODKPBV-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-2-methyl-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound C=1C=CN=CC=1C=1N=C2NC(C)=NC2=CC=1C1=CC=NC=C1F OGFQRMVUODKPBV-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- IERSHQMSCGIMDP-UHFFFAOYSA-N 2-cyclohexyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C1CCCCC1)=N2 IERSHQMSCGIMDP-UHFFFAOYSA-N 0.000 description 5
- FQFSWKVTOZFBOZ-UHFFFAOYSA-N 6-chloro-5-iodo-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=C(I)C=C1[N+]([O-])=O FQFSWKVTOZFBOZ-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VUWRRLUCWJCPMF-UHFFFAOYSA-N 3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC=C1Cl VUWRRLUCWJCPMF-UHFFFAOYSA-N 0.000 description 4
- KEWFVNBINRNTNV-UHFFFAOYSA-N 6-(1,3-oxazol-2-yl)-5-pyridin-4-ylpyridine-2,3-diamine Chemical compound N=1C=COC=1C=1N=C(N)C(N)=CC=1C1=CC=NC=C1 KEWFVNBINRNTNV-UHFFFAOYSA-N 0.000 description 4
- DRKNTNKZDWPWGD-UHFFFAOYSA-N 6-(1,3-oxazol-5-yl)-5-pyridin-4-ylpyridine-2,3-diamine Chemical compound C=1N=COC=1C=1N=C(N)C(N)=CC=1C1=CC=NC=C1 DRKNTNKZDWPWGD-UHFFFAOYSA-N 0.000 description 4
- NGTFCCQJTBXYKU-UHFFFAOYSA-N 6-chloro-5-(3-chloropyridin-4-yl)-3-nitropyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(Cl)=C1C1=CC=NC=C1Cl NGTFCCQJTBXYKU-UHFFFAOYSA-N 0.000 description 4
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 4
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 4
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000003880 polar aprotic solvent Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- QRKNVSIQSMRYLM-UHFFFAOYSA-N 3-nitro-6-[2-tri(propan-2-yl)silyl-1,3-oxazol-5-yl]pyridin-2-amine Chemical compound O1C([Si](C(C)C)(C(C)C)C(C)C)=NC=C1C1=CC=C([N+]([O-])=O)C(N)=N1 QRKNVSIQSMRYLM-UHFFFAOYSA-N 0.000 description 3
- DYIPPQWXLGIVRC-UHFFFAOYSA-N 5-(3-fluoropyridin-4-yl)-6-(1,3-oxazol-2-yl)pyridine-2,3-diamine Chemical compound N=1C=COC=1C=1N=C(N)C(N)=CC=1C1=CC=NC=C1F DYIPPQWXLGIVRC-UHFFFAOYSA-N 0.000 description 3
- WMVFCWBYEALFGT-UHFFFAOYSA-N 5-(3-fluoropyridin-4-yl)-6-(1,3-oxazol-5-yl)pyridine-2,3-diamine Chemical compound C=1N=COC=1C=1N=C(N)C(N)=CC=1C1=CC=NC=C1F WMVFCWBYEALFGT-UHFFFAOYSA-N 0.000 description 3
- GTSWWZQRFNEHQE-UHFFFAOYSA-N 5-bromo-3-nitro-6-pyridin-3-ylpyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2C=NC=CC=2)=C1Br GTSWWZQRFNEHQE-UHFFFAOYSA-N 0.000 description 3
- MLCVDABCSJGNKW-UHFFFAOYSA-N 5-bromo-6-(3-chloropyridin-4-yl)-3-nitropyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2C(=CN=CC=2)Cl)=C1Br MLCVDABCSJGNKW-UHFFFAOYSA-N 0.000 description 3
- WVSPEQZFJGYLMY-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound FC1=CN=CC=C1C(C(=N1)C=2OC=CN=2)=CC2=C1NC(=O)N2 WVSPEQZFJGYLMY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 101150078577 Adora2b gene Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000026030 halogenation Effects 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 150000003585 thioureas Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- HAODEOLEIIJMMV-UHFFFAOYSA-N (3,5-difluorophenyl)-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridin-2-yl]methanone Chemical compound FC1=CC(F)=CC(C(=O)C=2NC3=NC(=C(C=4C(=CN=CC=4)F)C=C3N=2)C=2C=NC=CC=2)=C1 HAODEOLEIIJMMV-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- ULGMSDJMITWSEY-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-pyridin-3-yl-6-pyridin-4-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NC2=CC(C=3C=CN=CC=3)=C(C=3C=NC=CC=3)N=C2N1 ULGMSDJMITWSEY-UHFFFAOYSA-N 0.000 description 2
- AZWKGGUSNXWIBG-UHFFFAOYSA-N 2-(6-methoxy-5-nitropyridin-2-yl)-1,3-oxazole Chemical compound C1=C([N+]([O-])=O)C(OC)=NC(C=2OC=CN=2)=C1 AZWKGGUSNXWIBG-UHFFFAOYSA-N 0.000 description 2
- PCSZTOZNVAACFY-UHFFFAOYSA-N 2-(6-pyridin-4-yl-1h-imidazo[4,5-b]pyridin-5-yl)-1,3-oxazole Chemical compound C1=COC(C=2C(=CC=3N=CNC=3N=2)C=2C=CN=CC=2)=N1 PCSZTOZNVAACFY-UHFFFAOYSA-N 0.000 description 2
- OPJFOSDWIWFYRW-UHFFFAOYSA-N 2-[6-(3-fluoropyridin-4-yl)-1h-imidazo[4,5-b]pyridin-5-yl]-1,3-oxazole Chemical compound FC1=CN=CC=C1C(C(=N1)C=2OC=CN=2)=CC2=C1NC=N2 OPJFOSDWIWFYRW-UHFFFAOYSA-N 0.000 description 2
- MBQKVCQJYQZTAF-UHFFFAOYSA-N 2-[6-[(4-methoxyphenyl)methyl]-5-nitropyridin-2-yl]-1,3-oxazole Chemical compound COC1=CC=C(CC2=NC(=CC=C2[N+](=O)[O-])C=2OC=CN=2)C=C1 MBQKVCQJYQZTAF-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- NBPQLPVAUZISNW-UHFFFAOYSA-N 2-cyclopropyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyridine Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(C1CC1)=N2 NBPQLPVAUZISNW-UHFFFAOYSA-N 0.000 description 2
- SEEILYQUMNMIDQ-UHFFFAOYSA-N 3-nitro-6-(1,3-oxazol-2-yl)-5-pyridin-4-ylpyridin-2-amine Chemical compound C=1C=NC=CC=1C=1C=C([N+]([O-])=O)C(N)=NC=1C1=NC=CO1 SEEILYQUMNMIDQ-UHFFFAOYSA-N 0.000 description 2
- YEORVBKKTIHVKX-UHFFFAOYSA-N 3-nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2OC=CN=2)=C1 YEORVBKKTIHVKX-UHFFFAOYSA-N 0.000 description 2
- JOICQOFBBBNORI-UHFFFAOYSA-N 3-nitro-6-pyridin-3-ylpyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2C=NC=CC=2)=C1 JOICQOFBBBNORI-UHFFFAOYSA-N 0.000 description 2
- NJGZLFGSYMUZSO-UHFFFAOYSA-N 3-nitro-6-pyridin-4-ylpyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2C=CN=CC=2)=C1 NJGZLFGSYMUZSO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VENIDIZFNHVWLJ-UHFFFAOYSA-N 5,6-bis(3-chloropyridin-4-yl)-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound ClC1=CN=CC=C1C(C(=N1)C=2C(=CN=CC=2)Cl)=CC2=C1NC(=O)N2 VENIDIZFNHVWLJ-UHFFFAOYSA-N 0.000 description 2
- GQCUXDBFVWFDHY-UHFFFAOYSA-N 5,6-dipyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C=1C=NC=CC=1C=1N=C2NC(=O)NC2=CC=1C1=CC=NC=C1 GQCUXDBFVWFDHY-UHFFFAOYSA-N 0.000 description 2
- SBEQWGQIHZWTFI-UHFFFAOYSA-N 5-(1,3-oxazol-2-yl)-6-pyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound N=1C=COC=1C=1N=C2NC(=O)NC2=CC=1C1=CC=NC=C1 SBEQWGQIHZWTFI-UHFFFAOYSA-N 0.000 description 2
- UHTCSZCOFYWPBM-UHFFFAOYSA-N 5-(3-fluoropyridin-4-yl)-3-nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine Chemical compound C=1C=NC=C(F)C=1C=1C=C([N+]([O-])=O)C(N)=NC=1C1=NC=CO1 UHTCSZCOFYWPBM-UHFFFAOYSA-N 0.000 description 2
- VHEUHISJNADBAE-UHFFFAOYSA-N 5-(3-fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound FC1=CN=CC=C1C(C(=C1)C=2C=CN=CC=2)=NC2=C1NC(=O)N2 VHEUHISJNADBAE-UHFFFAOYSA-N 0.000 description 2
- KTUQRRZIWJDXCS-UHFFFAOYSA-N 5-(6-pyridin-4-yl-1h-imidazo[4,5-b]pyridin-5-yl)-1,3-oxazole Chemical compound C=1N=COC=1C=1N=C2NC=NC2=CC=1C1=CC=NC=C1 KTUQRRZIWJDXCS-UHFFFAOYSA-N 0.000 description 2
- VAPFKAQLLVGEKA-UHFFFAOYSA-N 5-[6-(3-fluoropyridin-4-yl)-1h-imidazo[4,5-b]pyridin-5-yl]-1,3-oxazole Chemical compound FC1=CN=CC=C1C(C(=N1)C=2OC=NC=2)=CC2=C1NC=N2 VAPFKAQLLVGEKA-UHFFFAOYSA-N 0.000 description 2
- YLDZZXKJGXMJHQ-UHFFFAOYSA-N 5-bromo-3-nitro-6-[2-tri(propan-2-yl)silyl-1,3-oxazol-5-yl]pyridin-2-amine Chemical compound O1C([Si](C(C)C)(C(C)C)C(C)C)=NC=C1C1=NC(N)=C([N+]([O-])=O)C=C1Br YLDZZXKJGXMJHQ-UHFFFAOYSA-N 0.000 description 2
- JDDVEBLZYLTZDF-UHFFFAOYSA-N 5-bromo-3-nitro-6-pyridin-4-ylpyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2C=CN=CC=2)=C1Br JDDVEBLZYLTZDF-UHFFFAOYSA-N 0.000 description 2
- JJQJFZSQSRXLOY-UHFFFAOYSA-N 6-(3-chloropyridin-4-yl)-3-nitropyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2C(=CN=CC=2)Cl)=C1 JJQJFZSQSRXLOY-UHFFFAOYSA-N 0.000 description 2
- HHWZIYKSFXPFSB-UHFFFAOYSA-N 6-(3-chloropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound ClC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(=O)N2 HHWZIYKSFXPFSB-UHFFFAOYSA-N 0.000 description 2
- QAKYRFJMYLPPNY-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound FC1=CN=CC=C1C(C(=N1)C=2C=NC=CC=2)=CC2=C1NC(=O)N2 QAKYRFJMYLPPNY-UHFFFAOYSA-N 0.000 description 2
- HRVAXMNSTZAUIX-UHFFFAOYSA-N 6-chloro-3-nitro-5-pyridin-4-ylpyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(Cl)=C1C1=CC=NC=C1 HRVAXMNSTZAUIX-UHFFFAOYSA-N 0.000 description 2
- QOBVEZKFZOIFNE-UHFFFAOYSA-N 6-chloro-n,n-bis[(4-methoxyphenyl)methyl]-3-nitropyridin-2-amine Chemical compound C1=CC(OC)=CC=C1CN(C=1C(=CC=C(Cl)N=1)[N+]([O-])=O)CC1=CC=C(OC)C=C1 QOBVEZKFZOIFNE-UHFFFAOYSA-N 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- IIBBZZOMKXQSGL-UHFFFAOYSA-N n-[2-amino-5-(3-fluoropyridin-4-yl)-6-pyridin-3-ylpyridin-3-yl]-3-fluoro-4-methylbenzamide Chemical compound C1=C(F)C(C)=CC=C1C(=O)NC1=CC(C=2C(=CN=CC=2)F)=C(C=2C=NC=CC=2)N=C1N IIBBZZOMKXQSGL-UHFFFAOYSA-N 0.000 description 2
- BPHJYRHGVLFLBZ-UHFFFAOYSA-N n-[2-amino-5-(3-fluoropyridin-4-yl)-6-pyridin-3-ylpyridin-3-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC(C=2C(=CN=CC=2)F)=C(C=2C=NC=CC=2)N=C1N BPHJYRHGVLFLBZ-UHFFFAOYSA-N 0.000 description 2
- KJOSBIGXFYDLES-UHFFFAOYSA-N n-[2-amino-5-(3-fluoropyridin-4-yl)-6-pyridin-3-ylpyridin-3-yl]cyclopropanecarboxamide Chemical compound C=1C=NC=C(F)C=1C=1C=C(NC(=O)C2CC2)C(N)=NC=1C1=CC=CN=C1 KJOSBIGXFYDLES-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- PBDIANQBYUQMPW-UHFFFAOYSA-N 1,3-oxazol-2-yl-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)C1=NC=CO1 PBDIANQBYUQMPW-UHFFFAOYSA-N 0.000 description 1
- HBKPDEWGANZHJO-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-[(4-methoxyphenyl)methyl]methanamine Chemical compound C1=CC(OC)=CC=C1CNCC1=CC=C(OC)C=C1 HBKPDEWGANZHJO-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- MZZVFXMTZTVUFO-UHFFFAOYSA-N 1-chloro-4-isothiocyanatobenzene Chemical compound ClC1=CC=C(N=C=S)C=C1 MZZVFXMTZTVUFO-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- VITIPDJPNDEVKC-UHFFFAOYSA-N 2-[4-(3-fluoropyridin-4-yl)-6-[(4-methoxyphenyl)methyl]-5-nitropyridin-2-yl]-1,3-oxazole Chemical compound COC1=CC=C(CC2=NC(=CC(=C2[N+](=O)[O-])C2=C(C=NC=C2)F)C=2OC=CN=2)C=C1 VITIPDJPNDEVKC-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- MLFGHAHGSVFKMI-UHFFFAOYSA-N 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC=C1F MLFGHAHGSVFKMI-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- OKLOACZNEVKTCV-UHFFFAOYSA-N 3-nitro-6-(1,3-oxazol-5-yl)-5-pyridin-4-ylpyridin-2-amine Chemical compound C=1C=NC=CC=1C=1C=C([N+]([O-])=O)C(N)=NC=1C1=CN=CO1 OKLOACZNEVKTCV-UHFFFAOYSA-N 0.000 description 1
- BPYHGTCRXDWOIQ-UHFFFAOYSA-N 3-nitropyridin-2-amine Chemical class NC1=NC=CC=C1[N+]([O-])=O BPYHGTCRXDWOIQ-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- KBPBAPCTVKVIKQ-UHFFFAOYSA-N 5-(1,3-oxazol-5-yl)-6-pyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C=1N=COC=1C=1N=C2NC(=O)NC2=CC=1C1=CC=NC=C1 KBPBAPCTVKVIKQ-UHFFFAOYSA-N 0.000 description 1
- JTIDLXJFJVVPKS-UHFFFAOYSA-N 5-(3-fluoropyridin-4-yl)-3-nitro-6-(1,3-oxazol-5-yl)pyridin-2-amine Chemical compound C=1C=NC=C(F)C=1C=1C=C([N+]([O-])=O)C(N)=NC=1C1=CN=CO1 JTIDLXJFJVVPKS-UHFFFAOYSA-N 0.000 description 1
- MNLKRTCTWKXNST-UHFFFAOYSA-N 5-bromo-3-nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(C=2OC=CN=2)=C1Br MNLKRTCTWKXNST-UHFFFAOYSA-N 0.000 description 1
- YRXZIHANXVKUHP-UHFFFAOYSA-N 6-bromo-3-nitropyridin-2-amine Chemical compound NC1=NC(Br)=CC=C1[N+]([O-])=O YRXZIHANXVKUHP-UHFFFAOYSA-N 0.000 description 1
- OVVBXVJFGCFEFK-UHFFFAOYSA-N 6-chloro-2-methoxy-3-nitropyridine Chemical compound COC1=NC(Cl)=CC=C1[N+]([O-])=O OVVBXVJFGCFEFK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- IBDMRHDXAQZJAP-UHFFFAOYSA-N dichlorophosphorylbenzene Chemical compound ClP(Cl)(=O)C1=CC=CC=C1 IBDMRHDXAQZJAP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical group C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical compound CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000005619 secondary aliphatic amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 230000008477 smooth muscle tissue growth Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- TWSMTGCRUGWDPG-UHFFFAOYSA-N tri(propan-2-yl)-(5-tributylstannyl-1,3-oxazol-2-yl)silane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=C([Si](C(C)C)(C(C)C)C(C)C)O1 TWSMTGCRUGWDPG-UHFFFAOYSA-N 0.000 description 1
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- WIOADUFWOUUQCV-UHFFFAOYSA-N triphenylphosphanium dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 WIOADUFWOUUQCV-UHFFFAOYSA-N 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502433A ES2274712B1 (es) | 2005-10-06 | 2005-10-06 | Nuevos derivados imidazopiridina. |
| UY29836A UY29836A1 (es) | 2005-10-06 | 2006-10-03 | Nuevos derivados imidazopiridina |
| PE2006001205A PE20070706A1 (es) | 2005-10-06 | 2006-10-04 | Nuevos derivados imidazopiridina como antagonistas de adenosina a2b |
| KR1020087008297A KR20080050475A (ko) | 2005-10-06 | 2006-10-05 | Ａ2ｂ 아데노신 수용체 안타고니스트로서의 이미다조피리딘유도체 |
| TW095137259A TW200800985A (en) | 2005-10-06 | 2006-10-05 | New imidazopyridine derivatives |
| AU2006299028A AU2006299028A1 (en) | 2005-10-06 | 2006-10-05 | Imidazopyridine derivatives as A2B adenosine receptor antagonists |
| RU2008117329/04A RU2008117329A (ru) | 2005-10-06 | 2006-10-05 | Производные имидазопиридина как антагонисты аденозинового рецептора а2в |
| CNA2006800371946A CN101326181A (zh) | 2005-10-06 | 2006-10-05 | 作为a2b腺苷受体的拮抗体的咪唑吡啶衍生物 |
| US12/089,050 US7855202B2 (en) | 2005-10-06 | 2006-10-05 | Imidazopyridine derivatives as A2B adenosine receptor antagonists |
| CA002624879A CA2624879A1 (en) | 2005-10-06 | 2006-10-05 | Imidazopyridine derivatives as a2b adenosine receptor antagonists |
| JP2008533934A JP2009510152A (ja) | 2005-10-06 | 2006-10-05 | Ａ２ｂアデノシン受容体アンタゴニストとしての、イミダゾピリジン誘導体 |
| ARP060104379A AR055676A1 (es) | 2005-10-06 | 2006-10-05 | Derivados imidazopiridina |
| EP06806042A EP1931666A1 (en) | 2005-10-06 | 2006-10-05 | Imidazopyridine derivatives as a2b adenosine receptor antagonists |
| PCT/EP2006/009620 WO2007039297A1 (en) | 2005-10-06 | 2006-10-05 | Imidazopyridine derivatives as a2b adenosine receptor antagonists |
| ZA200802588A ZA200802588B (en) | 2005-10-06 | 2008-03-20 | Imidazopyridine derivatives as A2B adenosine receptor antagonists |
| IL190336A IL190336A0 (en) | 2005-10-06 | 2008-03-20 | Imidazopyridine derivatives as a2b adenosine receptor antagonists |
| EC2008008343A ECSP088343A (es) | 2005-10-06 | 2008-04-03 | Nuevos derivados imidazopiridina |
| NO20082121A NO20082121L (no) | 2005-10-06 | 2008-05-06 | Imidazopyridinderivater som A2B-adenosinreseptorantagonister |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502433A ES2274712B1 (es) | 2005-10-06 | 2005-10-06 | Nuevos derivados imidazopiridina. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2274712A1 ES2274712A1 (es) | 2007-05-16 |
| ES2274712B1 true ES2274712B1 (es) | 2008-03-01 |
Family
ID=36295447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200502433A Expired - Fee Related ES2274712B1 (es) | 2005-10-06 | 2005-10-06 | Nuevos derivados imidazopiridina. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7855202B2 (https=) |
| EP (1) | EP1931666A1 (https=) |
| JP (1) | JP2009510152A (https=) |
| KR (1) | KR20080050475A (https=) |
| CN (1) | CN101326181A (https=) |
| AR (1) | AR055676A1 (https=) |
| AU (1) | AU2006299028A1 (https=) |
| CA (1) | CA2624879A1 (https=) |
| EC (1) | ECSP088343A (https=) |
| ES (1) | ES2274712B1 (https=) |
| IL (1) | IL190336A0 (https=) |
| NO (1) | NO20082121L (https=) |
| PE (1) | PE20070706A1 (https=) |
| RU (1) | RU2008117329A (https=) |
| TW (1) | TW200800985A (https=) |
| UY (1) | UY29836A1 (https=) |
| WO (1) | WO2007039297A1 (https=) |
| ZA (1) | ZA200802588B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ATE543819T1 (de) | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| GEP20125379B (en) | 2007-05-03 | 2012-01-10 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| AU2008343813B2 (en) * | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| EP2294066B9 (en) * | 2008-04-28 | 2015-03-11 | Janssen Pharmaceutica, N.V. | Benzoimidazoles as prolyl hydroxylase inhibitors |
| WO2010133534A1 (en) * | 2009-05-19 | 2010-11-25 | Cellzome Limited | Bicyclic amino substituted compounds as pi3k inhibitors |
| EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| BR112012032766A2 (pt) | 2010-06-30 | 2019-09-24 | Gilead Sciences Inc | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar |
| WO2012033149A1 (ja) * | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| KR101913619B1 (ko) * | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| US9273034B2 (en) | 2011-10-25 | 2016-03-01 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid |
| JP2015515472A (ja) | 2012-04-06 | 2015-05-28 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害薬 |
| RU2644558C2 (ru) * | 2012-06-19 | 2018-02-13 | Сановьон Фармасьютикалз Инк. | Гетероарильные соединения и способы их применения |
| US9650376B2 (en) | 2013-03-15 | 2017-05-16 | Knopp Biosciences Llc | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| US11435340B2 (en) | 2014-06-09 | 2022-09-06 | Biometry Inc. | Low cost test strip and method to measure analyte |
| SI3572405T1 (sl) | 2014-09-12 | 2023-12-29 | Biohaven Therapeutics Ltd. | Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7 |
| ES2580702B1 (es) * | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| EP3487407B1 (en) | 2016-07-19 | 2024-10-02 | Biometry Inc. | Methods of and systems for measuring analytes using batch calibratable test strips |
| FI3562487T3 (fi) | 2016-12-29 | 2023-12-14 | Ji Xing Pharmaceuticals Hong Kong Ltd | Metalloentsyymi-inhibiittoriyhdisteitä |
| EP3562306B1 (en) | 2016-12-29 | 2025-02-26 | Ji Xing Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| US11312715B2 (en) | 2017-09-28 | 2022-04-26 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Fused ring derivative as A2A receptor inhibitor |
| ES2992256T3 (es) * | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| CA3126224A1 (en) | 2019-01-08 | 2020-07-16 | Corxel Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| WO2021095805A1 (ja) * | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤 |
| BR112022008571A2 (pt) | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003002566A1 (en) * | 2001-06-29 | 2003-01-09 | Cv Therapeutics, Inc. | Purine derivatives as a2b adenosine receptor antagonists |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9309573D0 (en) * | 1993-05-10 | 1993-06-23 | Merck Sharp & Dohme | Therapeutic agents |
| KR0151816B1 (ko) * | 1994-02-08 | 1998-10-15 | 강박광 | 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법 |
| US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| ES2304797T3 (es) | 1997-12-19 | 2008-10-16 | Amgen Inc. | Compuestos de piridina y piridazina sustituidos y su uso farmaceutico. |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| EP1208100B1 (en) | 1999-08-31 | 2003-04-02 | Vanderbilt University | Selective antagonists of a2b adenosine receptors |
| CA2400206A1 (en) | 2000-02-17 | 2001-08-23 | Cv Therapeutics, Inc. | Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| JP4064671B2 (ja) | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| KR20070058022A (ko) | 2000-04-26 | 2007-06-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 배변을 촉진하는 의약 조성물 |
| JP4251868B2 (ja) * | 2000-08-11 | 2009-04-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ２−アミノピリジン化合物および医薬用途 |
| AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP4122216B2 (ja) | 2000-09-19 | 2008-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＧＳＫ−３βタンパク質の特徴づけおよびその使用方法 |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| TWI330183B (https=) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| DK1444233T3 (da) | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US20050043315A1 (en) | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| MXPA03008967A (es) | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| EA200500005A1 (ru) | 2002-06-12 | 2005-06-30 | Байоджен Айдек Ма Инк. | Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина |
| US20040067955A1 (en) | 2002-09-06 | 2004-04-08 | Fujisawa Pharmaceutical Co. Ltd. | Pyridazinone compound and pharmaceutical use thereof |
| KR20120032574A (ko) | 2002-10-03 | 2012-04-05 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
| KR101312736B1 (ko) | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| DE60322748D1 (de) | 2003-05-06 | 2008-09-18 | Cv Therapeutics Inc | Xanthinderivate als a2b-adenosinrezeptorantagonisten |
| ES2557310T3 (es) | 2003-08-25 | 2016-01-25 | Dogwood Pharmaceuticals, Inc. | 8-heteroaril xantinas substituidas |
| ES2229928B1 (es) | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| GB0323138D0 (en) | 2003-10-03 | 2003-11-05 | Chang Lisa C W | Pyrimidines substituted in the 2,4,6 positions and their different uses |
| CA2543644A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| CA2544193C (en) | 2003-10-31 | 2012-03-27 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
| GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2303776B1 (es) | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
-
2005
- 2005-10-06 ES ES200502433A patent/ES2274712B1/es not_active Expired - Fee Related
-
2006
- 2006-10-03 UY UY29836A patent/UY29836A1/es unknown
- 2006-10-04 PE PE2006001205A patent/PE20070706A1/es not_active Application Discontinuation
- 2006-10-05 RU RU2008117329/04A patent/RU2008117329A/ru not_active Application Discontinuation
- 2006-10-05 AU AU2006299028A patent/AU2006299028A1/en not_active Abandoned
- 2006-10-05 KR KR1020087008297A patent/KR20080050475A/ko not_active Withdrawn
- 2006-10-05 CA CA002624879A patent/CA2624879A1/en not_active Abandoned
- 2006-10-05 AR ARP060104379A patent/AR055676A1/es unknown
- 2006-10-05 JP JP2008533934A patent/JP2009510152A/ja active Pending
- 2006-10-05 US US12/089,050 patent/US7855202B2/en not_active Expired - Fee Related
- 2006-10-05 WO PCT/EP2006/009620 patent/WO2007039297A1/en not_active Ceased
- 2006-10-05 EP EP06806042A patent/EP1931666A1/en not_active Withdrawn
- 2006-10-05 CN CNA2006800371946A patent/CN101326181A/zh active Pending
- 2006-10-05 TW TW095137259A patent/TW200800985A/zh unknown
-
2008
- 2008-03-20 ZA ZA200802588A patent/ZA200802588B/xx unknown
- 2008-03-20 IL IL190336A patent/IL190336A0/en unknown
- 2008-04-03 EC EC2008008343A patent/ECSP088343A/es unknown
- 2008-05-06 NO NO20082121A patent/NO20082121L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003002566A1 (en) * | 2001-06-29 | 2003-01-09 | Cv Therapeutics, Inc. | Purine derivatives as a2b adenosine receptor antagonists |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200802588B (en) | 2009-09-30 |
| AR055676A1 (es) | 2007-08-29 |
| WO2007039297A1 (en) | 2007-04-12 |
| ES2274712A1 (es) | 2007-05-16 |
| JP2009510152A (ja) | 2009-03-12 |
| RU2008117329A (ru) | 2009-11-20 |
| US7855202B2 (en) | 2010-12-21 |
| TW200800985A (en) | 2008-01-01 |
| UY29836A1 (es) | 2007-04-30 |
| US20080275038A1 (en) | 2008-11-06 |
| IL190336A0 (en) | 2009-09-22 |
| KR20080050475A (ko) | 2008-06-05 |
| CN101326181A (zh) | 2008-12-17 |
| CA2624879A1 (en) | 2007-04-12 |
| PE20070706A1 (es) | 2007-09-24 |
| AU2006299028A1 (en) | 2007-04-12 |
| NO20082121L (no) | 2008-07-07 |
| EP1931666A1 (en) | 2008-06-18 |
| ECSP088343A (es) | 2008-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2274712B1 (es) | Nuevos derivados imidazopiridina. | |
| ES2270715B1 (es) | Nuevos derivados de pirazina. | |
| ES2241496B1 (es) | Nuevos derivados de piridina. | |
| US10654832B2 (en) | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | |
| ES2914793T3 (es) | Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa | |
| ES2314690T3 (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de la map quinasa p38. | |
| EP2125804B1 (en) | 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one derivatives useful as a2b adenosine receptor antagonists | |
| CA2972148A1 (en) | Benzazepine dicarboxamide compounds | |
| JP2006512323A (ja) | 疼痛治療用ｖｒ−１アンタゴニストとしてのアミノ複素環 | |
| EA010487B1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора hгистамина | |
| EP1625119B1 (en) | Substituted-1-phthalazinamines as vr-1 antagonists | |
| US20040067955A1 (en) | Pyridazinone compound and pharmaceutical use thereof | |
| TW200804285A (en) | New pyridin-3-amine derivatives | |
| CN114656470B (zh) | 取代喹唑啉类化合物及其制备方法和应用 | |
| NZ732796B2 (en) | Benzazepine dicarboxamide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20070516 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2274712B1 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180809 |